Glycoprotein isolated from Acanthopanax senticosus protects against hepatotoxicity induced by acute and chronic alcohol treatment.
The protective effect of a 30 kDa glycoprotein (GF-AS) isolated from the stem bark of Acanthopanax senticosus against acute and chronic alcohol-induced hepatotoxicity were studied. N-terminal amino acid sequence of GF-AS showed NH(2)-Val-Ala-Tyr-Pro-Trp-Ala-Gly-Phe-Ala-Leu-Ser-Leu-Glx-Pro-Pro-Ala-Gly-Tyr-. GF-AS significantly increases the activities of alcohol-metabolizing enzymes, including alcohol dehydrogenase, microsomal ethanol metabolizing system, and acetaldehyde dehydrogenase in rats acutely treated with alcohol, resulting in decreased plasma alcohol levels. GF-AS also increases the activities of antioxidant enzymes and glutathione level. Markers of liver injury induced by alcohol: elevated serum levels of aspartate aminotransferase, alanine aminotransferase, triglyceride and cholesterol, are reduced by GF-AS in both acutely and chronically treated rats. The activities of lipogenic enzymes including malic enzyme, glucose-6-phosphate dehydrogenase, and 6-phosphoglucuronic acid dehydrogenase in chronic alcohol-treated rats are significantly decreased by GF-AS. Furthemore, GF-AS improves histological change in fatty liver and hepatic lesions induced by alcohol. Collectively, GF-AS may alleviate alcohol-induced hepatotoxicity through increasing ethanol and lipid metabolism, as well as antioxidant defense systems in livers injured by acute- and chronic-alcohol treatment.
Choi
Joo Sun
JS
Division of Metabolic Disease, Department of Biomedical Sciences, National Institute of Health, Seoul 122-701, Korea.
Yoon
Taek Joon
TJ
Kang
Kyung Ran
KR
Lee
Keyong Ho
KH
Lee
Kyeong Ho
KH
Kim
Won Ho
WH
Suh
Young Ho
YH
Song
Jihyun
J
Jung
Myeong Ho
MH
D000208:Acute Disease; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D004195:Disease Models, Animal; D028001:Eleutherococcus / Q000737:chemistry*; D006023:Glycoproteins / Q000302:isolation & purification / Q000627:therapeutic use*; D006519:Hepatitis, Alcoholic / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008099:Liver / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D008111:Liver Function Tests; D008297:Male; D051379:Mice; D020011:Protective Agents / Q000302:isolation & purification / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley
D006023:Glycoproteins; D008055:Lipids; D020011:Protective Agents